Struller Florian, Senne Moritz, Falch Claudius, Kirschniak Andreas, Konigsrainer Alfred, Muller Sven
Clinic for Visceral, General and Transplant Surgery, Tuebingen University Hospital, Germany.
Clinic for Visceral, General and Transplant Surgery, Tuebingen University Hospital, Germany.
Int J Surg Case Rep. 2017;37:36-40. doi: 10.1016/j.ijscr.2017.06.011. Epub 2017 Jun 13.
Primary squamous cell cancer (PSCC) of thyroid is a rare malignancy with poor prognosis. It is mandatory to exclude secondary involvement of the thyroid by panendoscopy, CT-scan and immunohistochemical analysis. As treatment surgery, radiation and rarely chemotherapy is employed.
A systematic review of the literature was conducted searching medline and embase database using the medical subject headings "primary squamous cell carcinoma of thyroid" and "primary squamous cell cancer of thyroid", for articles published until April 2016 (n=1733). Of interest were the used treatment modalities and survival outcomes.
A total of 35 publications reporting on 50 cases including ours were finally analyzed. A curative treatment approach was described in 24 patients (48%). Additional radiotherapy, chemotherapy or radiochemotherapy was applied in 17, 7 and 7 patients respectively. Median overall survival was 6 months [range 0-48] for 47 patients. Disease free survival was only achieved in 8 patients with disease limited to the thyroid gland, complete surgical resection and additional radiotherapy or radiochemotherapy [reported median 20 months; range 12-48].
Reported disease free survival of PSCC of the thyroid was only achieved in patients with complete surgical resection in combination with adjuvant radio- and/or chemotherapy. However long term survival has not been reported in the literature yet.
甲状腺原发性鳞状细胞癌（PSCC）是一种罕见的恶性肿瘤，预后较差。必须通过全腔镜检查、CT扫描和免疫组化分析排除甲状腺的继发性受累。治疗方法采用手术、放疗，很少采用化疗。
对文献进行系统回顾，使用医学主题词“甲状腺原发性鳞状细胞癌”和“甲状腺原发性鳞状细胞癌”检索Medline和Embase数据库，检索截至2016年4月发表的文章（n = 1733）。关注的是所采用的治疗方式和生存结果。
最终分析了35篇报道50例病例（包括我们的病例）的文献。24例患者（48%）描述了根治性治疗方法。分别有17例、7例和7例患者接受了额外的放疗、化疗或放化疗。47例患者的中位总生存期为6个月[范围0 - 48个月]。仅8例甲状腺局限型疾病、完整手术切除并接受额外放疗或放化疗的患者实现了无病生存[报道的中位生存期为20个月；范围12 - 48个月]。
甲状腺PSCC报道的无病生存仅在完整手术切除联合辅助放疗和/或化疗的患者中实现。然而，文献中尚未报道长期生存情况。
